Treat phage like living antibiotics

Bacteriophage therapeutics has emerged as one of the few potential beacons that represent possible solutions to the growing global crisis of antimicrobial resistance. Bringing science to the bedside (and vice versa) will maximize the potential of this compelling opportunity.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Phage evolution: from sideshow to centre stage.


  1. 1.

    Rohwer, F., Maughan, H., Youle, M. & Hisakawa, N. Life in Our Phage World: A Centennial Field Guide to the Earth’s Most Diverse Inhabitants (Wholon, 2014).

  2. 2.

    Summers, W. C. Bacteriophage 2, 130–133 (2012).

  3. 3.

    Wommack, K. E. & Colwell, R. R. Microbiol. Mol. Biol. Rev. 64, 69–71 (2000).

  4. 4.

    Locey, K. J. & Lennon, J. T. Proc. Natl Acad. Sci. USA 24, 5970–5975 (2016).

  5. 5.

    Twort, F. W. Lancet 186, 1241–1243 (1915).

  6. 6.

    Fabijan, A. P. et al. Nat. Microbiol. (2020).

  7. 7.

    Doogue, M. P. & Polasek, T. M. Ther. Adv. Drug Saf. 4, 5–7 (2013).

  8. 8.

    Ramratnam, B. et al. Nat. Med. 6, 82–85 (2000).

Download references

Author information



Corresponding author

Correspondence to Robert T. Schooley.

Ethics declarations

Competing interests

R. T. S. serves as a consultant to CytoDyn and has stock options in CytoDyn and Antiva Biosciences. He is a member of the Gilead Sciences Scientific Advisory Board and previously served as an uncompensated member of the AmpliPhi Scientific Advisory Board. S. S. holds stock in Adaptive Phage Therapeutics and is an uncompensated scientific advisor to NextBiotics.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schooley, R.T., Strathdee, S. Treat phage like living antibiotics. Nat Microbiol 5, 391–392 (2020).

Download citation